Search results for "Axel"

showing 10 items of 257 documents

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.

2007

ABSTRACT Background A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration …

Adultmedicine.medical_specialtyOrganoplatinum CompoundsAnemiaSettore MED/06 - Oncologia MedicaOvarian cancer recurrencedocetaxel ovarian cancer recurrence oxaliplatinPhases of clinical researchDocetaxelGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedOvarian NeoplasmsLeukopeniabusiness.industryHematologyMiddle Agedmedicine.diseaseOxaliplatinSurgeryOxaliplatinRegimenTreatment OutcomeOncologyDocetaxelDocetaxel; Ovarian cancer recurrence; OxaliplatinToxicityFemaleTaxoidsmedicine.symptomNeoplasm Recurrence LocalOvarian cancerbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a G…

2011

Objectives: The objective of the study was to assess the feasibility, toxicity, and reasons for early discontinuation of a modified outpatient intraperitoneal/intravenous (IP/IV) chemotherapy regimen for the treatment of patients with optimally debulked stage III ovarian cancer. Methods: Between February 2006 and November 2008, 51 consecutive patients from Institutions of the Spanish Ovarian Cancer Group (GEICO) were treated with a modified outpatient IP chemotherapy regimen. Patients received IV paclitaxel 175 mg/m2 over 3 hours on day 1, followed by IP cisplatin 100 mg/m2 (or 75 mg/m2 according to the principal investigator9s criteria) on day 2. On day 8, patients received IP paclitaxel 6…

Adultmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentNeutropeniaCarcinoma Ovarian EpithelialDrug Administration ScheduleAntineoplastic Combined Chemotherapy ProtocolsOutpatientsMedicineHumansInfusions ParenteralNeoplasms Glandular and EpithelialProspective StudiesProspective cohort studyInfusions IntravenousAgedNeoplasm StagingStage III Ovarian CancerOvarian NeoplasmsChemotherapybusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseaseChemotherapy regimenSurgeryClinical trialRegimenTreatment OutcomeOncologySpainFeasibility StudiesFemaleCisplatinbusinessOvarian cancerInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: An Italian clinical experience

2011

Aims and Background: We investigated the efficacy of docetaxel plus prednisone in Italian patients with metastatic hormone- refractory prostate cancer (mHRPC). Methods: Twenty four patients with mHRPC received docetaxel 75 mg/m2 every 3 weeks plus prednisone 5 mg twice daily for up to six cycles. The primary endpoint was efficacy measured by a reduction in serum prostate specific antigen (PSA) levels and measurable disease. Evaluation of toxicity, quality of life and reduction of pain were secondary endpoints. Results: PSA response was seen in 18 patients (75%). We observed a partial response in 2 patients (8.3%), stable disease in 10 patients (41.7%), and disease progression in 12 patients…

Aged 80 and overMaleTime FactorsAntineoplastic Agents HormonalSettore MED/06 - Oncologia MedicaProstatic NeoplasmsDocetaxelAdenocarcinomaMiddle AgedProstate-Specific AntigenTreatment OutcomeItalyDrug Resistance NeoplasmAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionHumansPrednisoneTaxoidsAdenocarcinoma Antineoplastic combined chemiotherapy protocols Docetaxel Drug-resistace Neoplasm Prednisone Prostatic neoplasm TaxoidsAgedNeoplasm Staging
researchProduct

Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells

1998

This paper deals with the apoptotic effect exerted in human retinoblastoma Y79 cells by a number of compounds. A remarkable effect was observed after treatment with DNA-damaging agents, such as camptothecin, etoposide, cisplatin and carboplatin; camptothecin was found to be the most efficacious. Treatment with these compounds induced the appearance of morphological features of apoptosis in the cells together with the distinct fragmentation of DNA, as shown by agarose gel electrophoresis. These effects were also accompanied by a remarkable increase in the level of p53. Many other compounds, which are not DNA-damaging agents, induced the morphological features of apoptosis but none of them we…

AmsacrinePaclitaxelDNA damageAntineoplastic AgentsApoptosisSuraminDNA ladderingBiologyretinoblastomaCarboplatinchemistry.chemical_compoundTumor Cells CulturedmedicineHumansFragmentation (cell biology)EtoposideCisplatinSodium butyrateGeneral MedicineAntineoplastic Agents PhytogenicMolecular biologyButyrateschemistryApoptosisAgarose gel electrophoresisImmunologyButyric AcidCamptothecinCisplatinDrug Screening Assays AntitumorCamptothecinDNA Damagemedicine.drug
researchProduct

Axel Honneth. La torsione hegeliana della Teoria critica

2012

Recensione di E. Piromalli, Axel Honneth.Giustizia sociale come riconoscimento, Mimesis 2012.

Axel Honneth riconoscimento Teoria critica
researchProduct

Book Review : Freedom’s Right. The Social Foundations of Democratic Life

2015

Axel Honnethbook review
researchProduct

Acute Laryngitis in the Rat Induced by Moraxella catarrhalis and Bordetella pertussis: Number of Neutrophils, Dendritic Cells, and T and B Lymphocyte…

1999

Infectious laryngotracheitis results in fulminant respiratory distress. During the disease, the subglottic mucosa is selectively infected and swollen, the reason for this preference being unknown. Therefore, in the present study the immunoreaction of the laryngeal mucosa was studied in the rat after inhalation of either heat-killed Moraxella catarrhalis (PVG rats) or application of viable Bordetella pertussis (BN rats). The number of neutrophils, macrophages, dendritic cells, and T and B lymphocytes was determined in the mucosa of the supraglottic, glottic, and subglottic area of the larynx as well as in the trachea. After application of the pathogens, the mucosa of the subglottic area was …

Bordetella pertussisPathologymedicine.medical_specialtyNeutrophilsWhooping CoughNeisseriaceae InfectionsT-LymphocytesInflammationGranulocyteBordetella pertussisMoraxella catarrhalisLaryngitismedicineAnimalsImmunity MucosalB-Lymphocytesbiologybusiness.industryRespiratory diseaseDendritic CellsT lymphocyteDendritic cellbiology.organism_classificationmedicine.diseaseEpitheliumBlood Cell CountRatsmedicine.anatomical_structureLaryngeal MucosaOrgan SpecificityPediatrics Perinatology and Child HealthImmunologymedicine.symptombusinessMoraxella catarrhalisPediatric Research
researchProduct

SNPs and taxane toxicity in breast cancer patients

2014

Aim: In order to identify genetic variants associated with taxanes toxicity, a panel with 47 SNPs in 20 genes involved in taxane pathways was designed. Patients & methods: Genomic DNA of 113 breast cancer patients was analyzed (70 taking docetaxel, 43 taking paclitaxel). Results: Two SNPs associated with docetaxel toxicity were identified: CYP3A4*1B with infusion-related reactions; and ERCC1 Gln504Lys with mucositis (p ≤ 0.01). Regarding paclitaxel toxicity: CYP2C8 HapC and CYP2C8 rs1934951 were associated with anemia; and ERCC1 Gln504Lys with neuropathy (p ≤ 0.01). Conclusion: Genes involved in DNA repair mechanisms and reactive oxygen species levels influence taxane toxicity in cance…

Bridged-Ring CompoundsMucositisOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPaclitaxelmedicine.medical_treatmentBreast NeoplasmsDocetaxelPharmacologyPolymorphism Single Nucleotidechemistry.chemical_compoundBreast cancerInternal medicineGeneticsMucositisCytochrome P-450 CYP3AHumansMedicineGenetic Association StudiesAgedPharmacologyChemotherapyTaxanebusiness.industryCancerMiddle AgedEndonucleasesmedicine.diseaseDNA-Binding ProteinsDocetaxelPaclitaxelchemistryMolecular MedicineFemaleTaxoidsERCC1businessmedicine.drugPharmacogenomics
researchProduct

Abstract B09: Nintedanib inhibits tumor and vessel growth and leads to vascular normalization in A549-NSCLC-xenografts

2015

Abstract Angiogenesis plays a major role in the growth and progression of non-small-cell lung cancer (NSCLC). The triple angiokinase inhibitor nintedanib is a potent inhibitor of the receptor tyrosine kinases FGFR-1, 2, 3, PDGFR-α and β, VEGFR-1, 2, 3. and Flt-3. as well as of non-receptor tyrosine kinases like Src, Lyn and Lck by occupying the intracellular ATP-binding pocket. In the pivotal LUME-Lung 1 trial Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma. The aim of this study was to analyse treatment induced vascular normalization of nintedanib, bevacizumab and docetaxel …

Cancer ResearchBevacizumabAngiogenesisbusiness.industryCancermedicine.diseaseLymphangiogenesischemistry.chemical_compoundOncologyDocetaxelchemistryImmunologyCancer researchMedicineAdenocarcinomaNintedanibbusinessLung cancermedicine.drugMolecular Cancer Therapeutics
researchProduct

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour …

2016

Abstract Objective To establishing whether neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is superior primary debulking surgery (PDS) in terms of clinical outcome as well as peri-operative morbidity in advanced epithelial ovarian cancer (AEOC) endowed with high tumour load (HTL). Material and methods This is a single-Institution, superiority, randomised phase III trial enrolling supposed AEOC women. Patients considered pre-operatively eligible were triaged to staging laparoscopy to assess the predictive index (PI) of tumour load. All AEOC women with PI ≥ 8 or ≤ 12 (considered as HTL) were included. They were randomly assigned (1:1 ratio) to undergo either PDS f…

Cancer ResearchCarcinoma Ovarian EpithelialRandomised clinical trialCarboplatinCytoreductionchemistry.chemical_compoundPostoperative Complications0302 clinical medicineQuality of lifeAntineoplastic Combined Chemotherapy ProtocolsNeoplasms Glandular and EpithelialOvarian Neoplasms030219 obstetrics & reproductive medicineCytoreduction Surgical ProceduresMiddle AgedDebulkingOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemalemedicine.symptomAdultQuality of lifemedicine.medical_specialtyAdolescentPaclitaxelNauseaOperative TimeYoung Adult03 medical and health sciencesOvarian cancerBody ImagemedicineHumansProgression-free survivalAgedAnalysis of VarianceAdvanced ovarian cancer; Cytoreduction; Laparoscopy; Peri-operative complications; Quality of life; Randomised clinical trialbusiness.industryPeri-operative complicationsPerioperativeLength of StayCarboplatinSurgeryClinical trialSettore MED/40 - GINECOLOGIA E OSTETRICIAchemistryAdvanced ovarian cancerLaparoscopyPeri-operative complicationComplicationbusiness
researchProduct